• Return to Headlines

Epizyme Inc has the Lowest Debt-to-Capital Ratio in the Biotechnology Industry (EPZM, ACHN, MGNX, ENTA, NLNK)

By David Diaz

Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Epizyme Inc ranks lowest with a a Debt-to-Capital ratio of 4.7%. Achillion Pharma is next with a a Debt-to-Capital ratio of 9.3%. Macrogenics Inc ranks third lowest with a a Debt-to-Capital ratio of 9.9%.

Enanta Pharmaceu follows with a a Debt-to-Capital ratio of 15.2%, and Newlink Genetics rounds out the bottom five with a a Debt-to-Capital ratio of 17.8%.

SmarTrend is tracking the current trend status for Epizyme Inc and will alert subscribers who have EPZM in their portfolio or watchlist when shares have changed trend direction.

Keywords: lowest debt-to-capital ratio epizyme inc achillion pharma macrogenics inc enanta pharmaceu newlink genetics

Ticker(s): EPZM ACHN MGNX ENTA NLNK